Sanctuary Advisors’s Royalty Pharma RPRX Stock Holding History

Sanctuary Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$409K	Buy	7,287 +1,075	+17%	+$56K	﹤0.01%	2120
2026 Q1	$298K	Buy	+6,212	New	+$272K	﹤0.01%	2104
2025 Q3	–	Sell	-15,612	Closed	-$562K	–	2528
2025 Q2	$562K	Sell	15,612 -8,339	-35%	-$276K	﹤0.01%	1563
2025 Q1	$746K	Sell	23,951 -17,903	-43%	-$567K	0.01%	1269
2024 Q4	$1.32M	Buy	41,854 +388	+0.9%	+$10.3K	0.01%	1087
2024 Q3	$1.1M	Buy	41,466 +18,288	+79%	+$507K	0.01%	1209
2024 Q2	$649K	Buy	+23,178	New	+$643K	﹤0.01%	1462

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sanctuary Advisors's RPRX Position: Q2 2026 in Review

Sanctuary Advisors increased its Royalty Pharma (RPRX) stake by 17% in Q2 2026, buying an estimated $56K and bringing the position to 7,287 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #2120.

Sanctuary Advisors first reported a position in RPRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.32M in Q4 2024. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Sanctuary Advisors held 7,287 shares of Royalty Pharma worth $409K as of Q2 2026.
Sanctuary Advisors bought 1,075 Royalty Pharma shares in Q2 2026, an estimated $56K.
Royalty Pharma made up ﹤0.01% of Sanctuary Advisors's portfolio in Q2 2026, its #2120 holding.
Sanctuary Advisors first reported a position in Royalty Pharma in Q2 2024 and has held it in 7 quarters since.
Sanctuary Advisors's Royalty Pharma position peaked at $1.32M in Q4 2024.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Sanctuary Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.